TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT

Életkor

• age < 18 years or > 75 years;

Egyéb

• recurrent HCC;
• PVTT at I-II grade by Cheng's criteria;
• advanced HCC with more than five metastases;
• Number of Intrahepatic tumors were more than five;
• no response to Lenvatinib;
• life expectancy less than 3 months.

• diagnosis of primary HCC, confirmed histologically or clinically according to the criteria of the American Association for the Study of Liver Diseases;
• presence of PVTT with III-IV grade by Cheng's criteria;
• having PVTT induced portal hypertension;
• with or without PVTT induced acute variceal bleeding;
• metastases with limited five sites and no more two organs involved;
• Number of Intrahepatic tumors were no more than five;
• receipt of Lenvatinib and PD-1 inhibitor as the first-line systemic therapy;
• classified as Child-Pugh class A or B and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 2;
• no history of other malignancies;
• agreed to participated in this clinical trial;
• Hemameba ≥3.0 x109/L, neutrophil ≥1.5x109/L, hemoglobin≥10.0 g/L, platelet≥100x 109/L, ALT; AST; bilirubin ≤1.5-fold normal, GFR≥60ml/min.